GlobalData on MSN17h
BMS receives FDA approval for Opdivo to treat NSCLC
Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults ...
Cure Today8h
Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC
Patients with muscle-invasive bladder cancer experienced safe medical and surgical treatment with the NURE-combo.
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
The American Journal of Managed Care14h
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
Cancer Therapy Advisor15h
Opdivo Approved in Neoadjuvant and Adjuvant Setting for Resectable NSCLC
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
The Pharma Letter19h
FDA approves Opdivo for lung cancer before and after surgery
Bristol Myers Squibb has received FDA approval for Opdivo (nivolumab) combined with chemotherapy as a perioperative treatment ...
FiercePharma1d
BMS' Opdivo joins the perioperative lung cancer treatment ring with key FDA approval
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
pharmaphorum18h
FDA approval give BMS an edge in NSCLC treatment
In 2023, BMS received a similar approval across the pond. The National Institute for Health and Care Excellence (NICE) ...
BioSpace16h
BMS Wins FDA Nod for Perioperative Opdivo Regimen in NSCLC
Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
Bristol-Myers wins FDA nod for Opdivo lung cancer indication
The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb ...
Monthly Prescribing Reference1d
Neoadjuvant/Adjuvant Opdivo Approved for Resectable NSCLC
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.